कंपनी का अवलोकन
CareDx, Inc. is a prominent entity within the healthcare sector, specifically operating in the diagnostics and research industry by providing advanced solutions designed to improve clinical outcomes for transplant patients and advance organ health management both domestically and internationally. The firm's core portfolio includes the AlloSure Kidney, which utilizes donor-derived cell-free DNA technology for kidney transplant monitoring, alongside the AlloMap Heart, a gene expression-based solution for heart disease diagnostics. This specialized operational scope places the company at the intersection of medical innovation and patient care, serving a niche but critical segment of the global organ transplant and cardiovascular health markets. In terms of scale, the company commands a market capitalization of $858.41M and generates annual revenue of $379.80M TTM while employing a workforce of 761 individuals. These valuation and revenue figures indicate that CareDx holds a significant position as a mid-to-large-cap player within its specialized diagnostic niche, possessing substantial resources to fund research and development in organ health technologies.
वित्तीय स्वास्थ्य
The company reports a trailing twelve-month revenue of $379.80M, yet this is accompanied by a net income of -$21,354,000 and an EBITDA of -$7,795,000, revealing a distinct gap between top-line growth and bottom-line profitability that points to a high cost structure or significant investment in R&D and operational expansion. Despite the reported net losses, the company maintains a robust free cash flow of $45.75M, which signifies strong operational efficiency and provides the financial flexibility necessary to fund capital expenditures, repay debt, or invest in new product pipelines without immediate external financing. The margin profile shows a gross margin of 67.6%, indicating high pricing power and efficient production of diagnostic kits, whereas the operating margin stands at -3.5% and the profit margin at -5.6%, highlighting that high overhead costs or sales expenses are currently eroding overall profitability. On the balance sheet, the company holds $177.21M in cash against $26.19M in debt, resulting in a debt-to-equity ratio of 8.64, which suggests a highly leveraged capital structure relative to equity, though the substantial cash reserves act as a significant buffer against this leverage. Liquidity is further supported by a current ratio of 2.86, indicating that the company possesses ample short-term assets to cover its current liabilities comfortably. Finally, the return on equity is -6.3% and the return on assets is -3.2%, metrics that reveal that management is currently generating negative returns on the capital employed, a common characteristic for growth-stage biotech and diagnostic firms investing heavily in future market share.
मूल्यांकन आकलन
Valuation metrics for CareDx present a complex picture given the company's profitability status, with a trailing P/E ratio listed as N/A due to net losses, while the forward P/E is calculated at 15.29, implying that the market expects a significant turnaround in earnings trajectory to justify current share prices. The price-to-book ratio stands at 2.80, suggesting that the market values the company at a substantial premium over its book value, likely reflecting the intangible value of its proprietary diagnostic technologies and intellectual property. Alternative valuation measures such as the price-to-sales ratio of 2.26 and an EV/EBITDA of -90.29 provide additional context, indicating that investors are pricing the stock based on sales growth potential rather than current earnings power. The stock's trading range over the past year spans from a low of $10.96 to a high of $21.48, meaning the current price sits dynamically within this band depending on market sentiment, though the specific current price is not provided to calculate the exact percentage below the high. The company exhibits a beta of 2.54, which indicates that its share price is highly volatile and tends to fluctuate with significantly greater magnitude than the broader market, reflecting the inherent risks associated with the healthcare and biotechnology sectors.
Growth & Income
CareDx demonstrates a robust revenue growth rate of 25.2% year-over-year, while earnings growth is listed as N/A due to the company's current unprofitability, implying that top-line expansion is currently prioritizing market penetration over immediate earnings generation. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, which confirms that management retains all earnings to reinvest directly into research, development, and business expansion rather than distributing cash to shareholders. This strategic choice to forego dividends aligns with the company's lifecycle stage, where capital is required to commercialize new diagnostics and secure regulatory approvals for transplant solutions. The overall growth and income profile characterizes CareDx as a high-growth, non-income stock where value is derived entirely from future revenue potential and technological advancements rather than current cash distributions or earnings stability.